Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

News feed

SFI shares rose 16% amid reports of a mysterious deal

16:57 SFIN

OGK-2 production decreased by 3% in 2025%

15:42 OGKB

Shareholders of Vladimir Chemical Plant approved dividends

13:55 VLHZ

Astra plans to attract a strategic investor

11:19 ASTR

Whoosh plans to double its fleet in Latin America

10:18 WUSH

Whoosh audience in 2025 grew by 22%

10:07 WUSH

Ivan Potapov has been appointed General Director of the MMCB

1/16/26 GEMA

Ozon to launch DFA platform

1/16/26 OZON

Ozon Pharmaceuticals expands the range of the Immunotresan drug

1/16/26 OZPH

En+ Group to build in Siberia 1 GW thermal power plant

1/16/26 ENPG